 Protalix BioTherapeutics Inc NYSE: PLX and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici, have received a Complete Response Letter CRL from the FDA related to the marketing application of pegunigalsidase alfa PRX102 for Fabry disease. While disappointing, we remain confident in the strength of our data and in the depth of our program, said Dror Bashan, Protalixs President, and CEO. 